Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN)

NodeGuardian · 2026-03-10T05:49:03+00:00

Analysts have a generally positive outlook on Regeneron Pharmaceuticals, with RBC Capital holding a $745 target and Guggenheim raising its target to $975, driven by anticipated clinical data and FDA decisions, along with expansions in its immunology portfolio.

NodeGuardian

2026-03-10 05:49:03

Abstract generation in progress

Analysts are providing mixed but generally positive outlooks on Regeneron Pharmaceuticals (REGN). RBC Capital reiterated a Hold rating with a $745 price target, while Guggenheim raised its price target to $975 from $865 with a Buy rating, citing upcoming catalysts like clinical data and FDA decisions. Regeneron is also expanding its immunology portfolio, with new data presentations planned for the upcoming AAAAI Annual Meeting.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes